In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Foghorn Therapeutics (FHTX – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $6.85.
According to TipRanks, Purohit is an analyst with an average return of -27.5% and a 19.40% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Genmab, and Axsome Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Foghorn Therapeutics with a $15.50 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $18.12 and a one-year low of $4.51. Currently, Foghorn Therapeutics has an average volume of 100.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Read More on FHTX:
- Foghorn Therapeutics price target lowered to $19 from $21 at Goldman Sachs
- Foghorn FHD-286 discontinuation a net positive, says H.C. Wainwright
- Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
- Foghorn Therapeutics announces data from Phase 1 study of FHD-286
- Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
